• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].

作者信息

Li Y L, Shi J, Liu F Z, Dong X Y, Wu C Y, Cheng W, Huang Z F, Zhu Z M

机构信息

Hematological Institute of Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, Zhengzhou 450003, China.

Laboratory of Henan Provincial People's Hospital, Zhengzhou 450003, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):70-74. doi: 10.3760/cma.j.issn.0253-2727.2022.01.014.

DOI:10.3760/cma.j.issn.0253-2727.2022.01.014
PMID:35231997
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8980656/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/c0ee4ac10d37/cjh-43-01-070-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/e499ed86d6dd/cjh-43-01-070-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/b1dd43ceb81c/cjh-43-01-070-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/c0ee4ac10d37/cjh-43-01-070-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/e499ed86d6dd/cjh-43-01-070-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/b1dd43ceb81c/cjh-43-01-070-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e7c6/8980656/c0ee4ac10d37/cjh-43-01-070-g003.jpg

相似文献

1
[The significance of bone marrow immature plasma cell burden in the prognosis of newly diagnosed multiple myeloma patients].[骨髓未成熟浆细胞负荷在新诊断的多发性骨髓瘤患者预后中的意义]
Zhonghua Xue Ye Xue Za Zhi. 2022 Jan 14;43(1):70-74. doi: 10.3760/cma.j.issn.0253-2727.2022.01.014.
2
Plasma cell morphology in multiple myeloma and related disorders.多发性骨髓瘤及相关疾病中的浆细胞形态学。
Morphologie. 2015 Jun;99(325):38-62. doi: 10.1016/j.morpho.2015.02.001. Epub 2015 Apr 18.
3
Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology.多发性骨髓瘤，第 3.2021 版，NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2020 Dec 2;18(12):1685-1717. doi: 10.6004/jnccn.2020.0057.
4
[Cytopathological features of multiple myeloma].[多发性骨髓瘤的细胞病理学特征]
Nihon Rinsho. 2007 Dec;65(12):2250-5.
5
[Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].36例初诊骨髓单克隆浆细胞比例低于10%的多发性骨髓瘤患者临床特征及预后分析
Zhonghua Xue Ye Xue Za Zhi. 2021 Apr 14;42(4):295-301. doi: 10.3760/cma.j.issn.0253-2727.2021.04.005.
6
Prognostic significance of plasma cell morphology in multiple myeloma.浆细胞形态在多发性骨髓瘤中的预后意义
Cancer. 1987 Sep 1;60(5):1060-5. doi: 10.1002/1097-0142(19870901)60:5<1060::aid-cncr2820600522>3.0.co;2-3.
7
Circulating Serum MicroRNA-130a as a Novel Putative Marker of Extramedullary Myeloma.循环血清微小RNA-130a作为髓外骨髓瘤的一种新型潜在标志物
PLoS One. 2015 Sep 21;10(9):e0137294. doi: 10.1371/journal.pone.0137294. eCollection 2015.
8
[Correlation analysis of polyclonal plasma cell proportion in the bone marrow with clinical characteristics of patients with newly diagnosed multiple myeloma].[初诊多发性骨髓瘤患者骨髓多克隆浆细胞比例与临床特征的相关性分析]
Zhonghua Xue Ye Xue Za Zhi. 2024 May 14;45(5):475-480. doi: 10.3760/cma.j.cn121090-20231020-00221.
9
Diagnosis and risk stratification in multiple myeloma.多发性骨髓瘤的诊断与风险分层
Hematol Oncol Clin North Am. 2014 Oct;28(5):791-813. doi: 10.1016/j.hoc.2014.06.007. Epub 2014 Jul 22.
10
Bone marrow plasmacytosis.骨髓浆细胞增多症。
S Afr Med J. 1951 Aug 25;25(34):597-9.

本文引用的文献

1
[Cytogenetic abnormalities and morphological changes of bone marrow in multiple myeloma: a pathological analysis of 151 cases].[多发性骨髓瘤的细胞遗传学异常及骨髓形态学改变：151例病例的病理分析]
Zhonghua Bing Li Xue Za Zhi. 2020 Nov 8;49(11):1136-1141. doi: 10.3760/cma.j.cn112151-20200306-00178.
2
Evaluation of Angiogenesis in Multiple Myeloma by VEGF Immunoexpression and Microvessel Density.通过VEGF免疫表达和微血管密度评估多发性骨髓瘤中的血管生成
J Lab Physicians. 2020 Mar;12(1):38-43. doi: 10.1055/s-0040-1714933. Epub 2020 Jul 24.
3
Morphologic Classification Is an Important Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib or Lenalidomide.
Ann Clin Lab Sci. 2020 May;50(3):333-341.
4
Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients.骨髓浆细胞比例升高可预测初诊多发性骨髓瘤患者的预后。
Clin Lymphoma Myeloma Leuk. 2020 Sep;20(9):596-601. doi: 10.1016/j.clml.2020.03.012. Epub 2020 Apr 7.
5
Molecular basis of clonal evolution in multiple myeloma.多发性骨髓瘤克隆进化的分子基础。
Int J Hematol. 2020 Apr;111(4):496-511. doi: 10.1007/s12185-020-02829-6. Epub 2020 Feb 6.
6
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone.染色体 1q 的获得与接受来那度胺、硼替佐米和地塞米松治疗的多发性骨髓瘤患者的早期进展相关。
Blood Cancer J. 2019 Nov 25;9(12):94. doi: 10.1038/s41408-019-0254-0.
7
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.新诊断骨髓瘤的预后预测：1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
8
Plasma cell maturity as a predictor of prognosis in multiple myeloma.浆细胞成熟度作为多发性骨髓瘤预后的预测指标
Med Oncol. 2016 Aug;33(8):87. doi: 10.1007/s12032-016-0803-3. Epub 2016 Jul 6.
9
Validation of interphase fluorescence in situ hybridization (iFISH) for multiple myeloma using CD138 positive cells.使用CD138阳性细胞对多发性骨髓瘤进行间期荧光原位杂交（iFISH）验证。
Rev Bras Hematol Hemoter. 2016 Apr-Jun;38(2):113-20. doi: 10.1016/j.bjhh.2016.01.005. Epub 2016 Feb 23.
10
Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.浆母细胞性多发性骨髓瘤的临床病理特征：一项基于人群的队列研究
APMIS. 2015 Aug;123(8):652-8. doi: 10.1111/apm.12411. Epub 2015 Jul 8.